Global Atopic Dermatitis Pipeline Insight Research Report 2021 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Atopic Dermatitis - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
This "Atopic Dermatitis - Pipeline Insight, 2021," report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Atopic Dermatitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Atopic Dermatitis Emerging Drugs Chapters
This segment of the Atopic Dermatitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Atopic Dermatitis Emerging Drugs
Abrocitinib (PF-04965842) is an oral, small molecule that selectively inhibits Janus kinase (JAK) 1. Inhibition of JAK1 modulates multiple cytokines involved in the pathophysiology of AD, including interleukin (IL)-4, IL-13, IL-31, IL-22, and thymic stromal lymphopoietin (TSLP). The drug received breakthrough therapy designation from the FDA to treat patients with moderate-to-severe AD in February 2018. In October 2020, based on the results of a robust Phase III clinical trial program, the FDA, accepted the filing of the company's NDA for abrocitinib (100 mg and 200 mg) and granted priority review designation; the decision is anticipated April 2021. EMA accepted the MAA for the drug in the same patient population with a decision anticipated in the second half of 2021.
Upadacitinib (ABT-494) was discovered and developed by AbbVie. It is a selective and reversible JAK inhibitor that was approved by FDA and EMA in August 2019 and December 2019, respectively, for adult patients with moderately to severely active rheumatoid arthritis. The drug is currently under clinical developmental studies for atopic dermatitis, and several other immune-mediated diseases. - In October 2020, AbbVie submitted an application to the FDA and EMA seeking approval for Rinvoq for the treatment of adults (15 mg and 30 mg, once daily) and adolescents (15 mg, once daily) with moderate-to-severe AD. The atopic dermatitis indication applications to the FDA and EMA are supported by data from three pivotal Phase 3 studies.
Tradipitant: Vanda Pharmaceuticals
Tradipitant is a small molecule based neurokinin 1 (NK1) receptor antagonist. Tradipitant is currently in phase III clinical development for gastroparesis, COVID-19 pneumonia, motion sickness and atopic dermatitis. Tradipitant licensed by Vanda from Eli Lilly and Company (Lilly) in April 2012. The patent describing tradipitant as a new chemical entity expires worldwide in April 2023, except in the United States, where it expires in June 2024.
Nemolizumab (CD14152) is a subcutaneously administered monoclonal antibody that antagonizes IL-31RA, a cytokine that plays a key role in the pathogenesis of moderate-to-severe AD, thereby blocking IL-31 signaling on its effector cells, including peripheral neurons. The drug was initially developed by Chugai Pharmaceutical and subsequently licensed to Galderma in 2016. Currently, the drug is being studied in Phase III trial as a once-daily oral therapy for moderate-to-severe AD in adults and in several other immune-mediated diseases.
Lebrikizumab: Eli Lilly and Company
Lebrikizumab is a novel, investigational, monoclonal antibody designed to bind IL-13 with very high affinity, specifically preventing the formation of the IL-13R1/IL-4R heterodimer complex and subsequent signaling, thereby inhibiting the biological effects of IL-13 in a targeted and efficient fashion. IL-13 is believed to be a central pathogenic mediator that drives multiple aspects of the pathophysiology of atopic dermatitis by promoting type 2 inflammation and mediating its effects on tissue, resulting in skin barrier dysfunction, itch, skin thickening, and infection. The drug is being evaluated in Phase III stage of development for the treatment of patients with Atopic dermatitis.
IDP 124: Ortho Dermatologics
Bausch Health Americas in collaboration with Ortho Dermatologics is developing IDP 124 for the treatment of patients with Atopic dermatitis. The drug is currently in phase 3 of clinical trials.
SHR0302: Reistone Biopharma
SHR0302 is a highly selective small molecule based JAK 1 inhibitor. Reistone licensed in the drug from Jiangsu Hengrui Medicine and owns the global rights for multiple indications of autoimmune diseases. Reistone Biopharma is developing SHR0302 in linical studies with both oral and topical dosage forms for several immune-inflammatory diseases including Ulcerative Colitis, Crohn's disease, etc. The high selectivity of SHR0302 may potentially provide a favorable safety and efficacy profile compared to the pan-JAK inhibitors.
MEDI 3506 is an IL-33 (interleukin-33) monoclonal antibody being developed by AstraZeneca for the treatment of Atopic Dermatitis and chronic diabetic kidney disease. The drug is currently being studied in phase II stage of development for the treatment of patients with Atopic Dermatitis.
Atopic Dermatitis: Therapeutic Assessment
This segment of the report provides insights about the different Atopic Dermatitis drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Atopic Dermatitis
There are approx. 100+ key companies which are developing the therapies for Atopic Dermatitis. The companies which have their Atopic Dermatitis drug candidates in the most advanced stage, i.e. Phase III include, Lysogene.
- Aclaris Therapeutics
- ACO Hud Nordic AB
- Arcutis Biotherapeutics
- Arena Pharmaceuticals
- Bellus Health
- Boehringer Ingelheim
- Botanix Pharmaceuticals
- Cara therapeutics
- Dermata Therapeutics
- DS Biopharma
- EHL Bio
- Eli Lilly and Company
- Forte Biosciences
- Golden Biotechnology Corporation
- Ichnos Sciences
- Incyte Corporation
- Kang Stem Biotech
- Keymed Biosciences
- Kymab Limite
- Kyowa Kirin
- Oneness Biotech
- Ortho Dermatologics
- Otsuka Pharmaceutical
- Ralexar Therapeutics
- Shulov Innovate for Science
- Spherium Biomed
- Sterna Biologicals
- Sun Pharmaceutical
- Suzhou Connect Biopharmaceuticals
- Suzhou Zelgen Biopharmaceuticals
- Taro Pharmaceuticals
- Teres Bio
- Tianjin Hemay Pharmaceutical
- Tioga Pharmaceuticals
- UNION therapeutics
- Vanda Pharmaceuticals
- Welichem Biotech
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/4jpj13
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900